Meet with Inoviv at
Biomarkers US 2024
Conference Details
Date: October 28-29
Meet with us at Booth #25
Location: San Diego, USA
About Inoviv
Explore the latest developments in the biomarker field through the 8th Annual Biomarker & Precision Medicine US Congress, which brings together experts from global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions all focussed on emerging tools and strategies within translational science, diagnostics and biomarker development.
Meet us at Booth #25 to discuss the following:
Biomarkers US
The conference brings together experts developing precision immunotherapies with scientists paving the way with biomarker strategies and diagnostic tools to enable precision treatments not just for oncology, but neuroscience, rare diseases, and more. With precision medicine also at the forefront, key opinion leaders will examine how these innovations are shaping the landscape of healthcare and the future of personalized treatment approaches within clinical trials.
Biomarker assay development & validation is challenging
Biomarkers discovered in preclinical models often fail to translate effectively into human studies due to genetic differences, environmental factors, and the presence of comorbidities
The shift from discovery to assay development requires the selection of biomarkers with measurable, reproducible, and scalable characteristics
There is a strong need for a single-point solution to help drug developers and researchers efficiently navigate the path from proteomic discovery to targeted assay validation, and regulatory approval
Proteomics and their utility as robust molecular fingerprints
Drug developers and researchers can efficiently identify dysregulated disease-modifying biomarkers, providing insights into mechanisms and treatment targets
In scenarios involving the discovery of novel biomarkers, the characterization of isoforms, or the need for quantitative accuracy for clinical application and monitoring, MS is often the superior choice
Robust LC-MS solutions for precision medicine development
Inoviv’s end-to-end discovery to targeted proteomics helps drug developers understand novel dysregulated disease-associated markers, and translate those findings into a fully validated targeted assay for treatment monitoring, disease staging, and more
Our proprietary analytical algorithms, workflows, and internal standards provide the highest possible reproducibility and robustness across thousands of samples with a linear dynamic range over six orders of magnitude
